Overview
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Eligibility
Inclusion Criteria:
- Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020
Exclusion Criteria:
- This is not applicable to this study


